Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Mysoline — MYSOLINE
Application NDA009170 (NDA)
Retin-A — RETIN-A
Application NDA016921 (NDA)
Retin-A — RETIN-A
Application NDA017579 (NDA)
Retin-A — RETIN-A
Application NDA017955 (NDA)
Permax — PERMAX
Application NDA019385 (NDA)
Retin-A — RETIN-A
Application NDA019049 (NDA)
Levo-Dromoran — LEVO-DROMORAN
Application NDA008719 (NDA)
Levo-Dromoran — LEVO-DROMORAN
Application NDA008720 (NDA)
Dermatop E Emollient — DERMATOP
Application NDA019568 (NDA)
Dermatop E Emollient — DERMATOP E EMOLLIENT
Application NDA020279 (NDA)
Retin-A — RENOVA
Application NDA019963 (NDA)
Retin-A — VESANOID
Application NDA020438 (NDA)
Retin-A — AVITA
Application NDA020404 (NDA)
Retin-A — AVITA
Application NDA020400 (NDA)
Retin-A — RENOVA
Application NDA021108 (NDA)
Colazal — COLAZAL
Application NDA020610 (NDA)
Retin-A — RETIN-A MICRO
Application NDA020475 (NDA)
Retin-A — ATRALIN
Application NDA022070 (NDA)
Colazal — GIAZO
Application NDA022205 (NDA)
Retin-A — ALTRENO
Application NDA209353 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)